BRCA1 protein
BRCA2 protein
ovarian cancer
Journal
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626
Informations de publication
Date de publication:
07 08 2023
07 08 2023
Historique:
medline:
9
8
2023
pubmed:
4
5
2023
entrez:
3
5
2023
Statut:
epublish
Résumé
Since 2015, Dutch guidelines have recommended To evaluate A consecutive series of 250 patients diagnosed with epithelial ovarian cancer between 2016 and 2019 was included from the OncoLifeS data-biobank of the University Medical Center Groningen, the Netherlands. Testing rates were analyzed for the overall study population and for germline testing (period I) and tumor-first testing (period II) separately. Characteristics of tested and untested patients were compared and predictors for receiving testing were assessed with multivariable logistic regression. Median age was 67.0 years (IQR 59.0-73.0) and 173 (69.2%) patients were diagnosed with high-grade serous carcinoma. Overall, 201 (80.4%) patients were tested. In period I, 137/171 (80.1%) patients were tested and in period II this was 64/79 (81.0%). Patients with non-high-grade serous carcinoma were significantly less likely to receive The results show that
Sections du résumé
BACKGROUND
Since 2015, Dutch guidelines have recommended
OBJECTIVE
To evaluate
METHODS
A consecutive series of 250 patients diagnosed with epithelial ovarian cancer between 2016 and 2019 was included from the OncoLifeS data-biobank of the University Medical Center Groningen, the Netherlands. Testing rates were analyzed for the overall study population and for germline testing (period I) and tumor-first testing (period II) separately. Characteristics of tested and untested patients were compared and predictors for receiving testing were assessed with multivariable logistic regression.
RESULTS
Median age was 67.0 years (IQR 59.0-73.0) and 173 (69.2%) patients were diagnosed with high-grade serous carcinoma. Overall, 201 (80.4%) patients were tested. In period I, 137/171 (80.1%) patients were tested and in period II this was 64/79 (81.0%). Patients with non-high-grade serous carcinoma were significantly less likely to receive
CONCLUSIONS
The results show that
Identifiants
pubmed: 37137525
pii: ijgc-2023-004307
doi: 10.1136/ijgc-2023-004307
pmc: PMC10423510
doi:
Substances chimiques
BRCA1 protein, human
0
BRCA1 Protein
0
BRCA2 protein, human
0
BRCA2 Protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1260-1269Informations de copyright
© IGCS and ESGO 2023. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: At the time of conducting this research, NA was an employee of, and held stock in, AstraZeneca LP. GdB and LL were financially supported by a grant from AstraZeneca for the purpose of this research project.
Références
J Clin Oncol. 2017 Dec 1;35(34):3800-3806
pubmed: 28820644
J Clin Oncol. 2012 Jul 20;30(21):2654-63
pubmed: 22711857
J Community Genet. 2017 Oct;8(4):303-310
pubmed: 28868568
Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18032-7
pubmed: 22006311
Maturitas. 2015 Mar;80(3):318-22
pubmed: 25600260
Gynecol Oncol. 2021 Aug;162(2):506-516
pubmed: 34023131
J Clin Oncol. 2019 May 20;37(15):1305-1315
pubmed: 30964716
Clin Oncol (R Coll Radiol). 2018 Aug;30(8):472-483
pubmed: 29735311
J Clin Oncol. 2010 Aug 1;28(22):3570-6
pubmed: 20606085
J Transl Med. 2019 Nov 14;17(1):374
pubmed: 31727094
J Ovarian Res. 2019 May 7;12(1):40
pubmed: 31064392
J Natl Cancer Inst. 2020 Feb 1;112(2):161-169
pubmed: 31076742
Gynecol Oncol. 2022 Jan;164(1):221-230
pubmed: 34702566
Cancers (Basel). 2018 Nov 13;10(11):
pubmed: 30428547